1. Academic Validation
  2. ICRF-193 modifies etoposide-induced apoptosis in thymocytes

ICRF-193 modifies etoposide-induced apoptosis in thymocytes

  • Acta Med Okayama. 1995 Dec;49(6):281-6. doi: 10.18926/AMO/30383.
C Tanimoto 1 S Hirakawa H Kawasaki N Hayakawa Z Ota
Affiliations

Affiliation

  • 1 Third Department of Internal Medicine, Okayama University Medical School, Japan.
Abstract

Etoposide (VP-16), one of the Topoisomerase II (TopoII) inhibitors, interferes with TopoII by inducing the formation of and stabilizing a cleavable enzyme-DNA complex. VP-16 has been demonstrated to induce Apoptosis in murine thymocytes. To clarify the mechanism of action of VP-16, we examined the in vitro effect of a non-cleavable-complex-forming type TopoII inhibitor, ICRF-193 which inhibits the DNA strand breakage induced by VP-16, on murine thymocytes in which Apoptosis had been induced with VP-16. DNA fragmentation is characteristic of Apoptosis. In the early stages, ICRF-193 decreased DNA fragmentation induced by VP-16, although this inhibitory effect decreased in the later. These data suggest that TopoII inhibitors induce Apoptosis in murine thymocytes in two ways: with DNA-strand breaks in the early stage or without them. ICRF-193 itself induced Apoptosis in murine thymocytes. The time course of DNA fragmentation caused by ICRF-193 was different from that of VP-16.

Figures
Products